Literature DB >> 33129978

Standardization of conventional chemoembolization for hepatocellular carcinoma.

Matteo Renzulli1, Giuliano Peta2, Francesco Vasuri3, Giovanni Marasco4, Daniele Caretti5, Laura Bartalena2, Daniele Spinelli2, Emanuela Giampalma6, Antonietta D'Errico3, Rita Golfieri2.   

Abstract

INTRODUCTION AND
OBJECTIVES: Conventional transarterial chemoembolization (cTACE) has several limitations due to the lack of standardization. The aim of this study was to evaluate the chemical and physical characteristics and behaviors over time of emulsions for cTACE and to assess intra- and inter-operator variabilities in the preparation processes.
MATERIALS AND METHODS: This in vitro study involved evaluation of emulsions for cTACE prepared using two methods: water-in-oil (WiO) and chemotherapeutic-in-oil (CiO). Three emulsions were prepared with each method and obtained after 20, 50, and 100 pumping exchanges. A drop from each final mixture was analyzed via light microscopy (time 1) and after 5, 10, 15, and 20min since the end of preparation. After 20min, all preparations were re-mixed and new drops were re-evaluated. The intra- and inter-operator variabilities were analyzed.
RESULTS: The mean droplet diameter decreased non-significantly when the number of pumping exchanges increased and increased significantly over time for both WiO and CiO. The droplets returned to their initial diameters after re-mixing. There were no significant differences in the intra- and inter-operator variabilities (P>0.01).
CONCLUSIONS: Any interventional radiologist, regardless of their experience, may prepare these emulsions. These data may represent a set of instructions to standardize cTACE.
Copyright © 2020 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Chemoembolization.; Hepatocellular carcinoma; Lipiodol

Mesh:

Substances:

Year:  2020        PMID: 33129978     DOI: 10.1016/j.aohep.2020.10.006

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  11 in total

Review 1.  Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma.

Authors:  Tarik Silk; Mikhail Silk; Jennifer Wu
Journal:  World J Gastroenterol       Date:  2022-06-21       Impact factor: 5.374

Review 2.  Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons.

Authors:  Mina S Makary; Stuart Ramsell; Eric Miller; Eliza W Beal; Joshua D Dowell
Journal:  World J Gastroenterol       Date:  2021-11-21       Impact factor: 5.742

3.  The first two cases of posterior reversible encephalopathy syndrome (PRES) secondary to conventional transcatheter arterial chemoembolization of hepatocellular carcinoma.

Authors:  Kefeng Jia; Weili Yin; Fang Wang; Zhongsong Gao; Cheng Sun; Hui Wang; Yujuan Han; Yongmei Wang; Mingge Li; Changlu Yu
Journal:  BMC Gastroenterol       Date:  2021-12-20       Impact factor: 3.067

4.  Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center.

Authors:  Shuguang Ju; Chen Zhou; Chongtu Yang; Chaoyang Wang; Jiacheng Liu; Yingliang Wang; Songjiang Huang; Tongqiang Li; Yang Chen; Yaowei Bai; Wei Yao; Bin Xiong
Journal:  Front Oncol       Date:  2022-01-31       Impact factor: 6.244

5.  Prognostic role of multiparameter MRI and radiomics in progression of advanced unresectable hepatocellular carcinoma following combined transcatheter arterial chemoembolization and lenvatinib therapy.

Authors:  Junpeng Luo; Zhimei Huang; Murong Wang; Tian Li; Jinhua Huang
Journal:  BMC Gastroenterol       Date:  2022-03-08       Impact factor: 3.067

6.  Diaphragmatic perforation after transcatheter arterial chemoembolization of hepatocellular carcinoma via inferior phrenic artery: a case report.

Authors:  Ji Soo Kim; Hyoung Nam Lee; Woong Hee Lee; Suk Hyun Bae
Journal:  BMC Gastroenterol       Date:  2022-02-05       Impact factor: 3.067

Review 7.  Initiative on Superselective Conventional Transarterial Chemoembolization Results (INSPIRE).

Authors:  Thierry de Baere; Maxime Ronot; Jin Wook Chung; Rita Golfieri; Roman Kloeckner; Joong-Won Park; Bernhard Gebauer; Nabil Kibriya; Ganapathy Ananthakrishnan; Shiro Miyayama
Journal:  Cardiovasc Intervent Radiol       Date:  2022-08-17       Impact factor: 2.797

8.  The Value of Contrast-Enhanced Magnetic Resonance Imaging Enhancement in the Differential Diagnosis of Hepatocellular Carcinoma and Combined Hepatocellular Cholangiocarinoma.

Authors:  Lun Lu; ChenCai Zhang; Xian Yu; Ling Zhang; YaYuan Feng; YuXian Wu; JinJu Xia; Xue Chen; RuiPing Zhang; Juan Zhang; Ningyang Jia; SiSi Zhang
Journal:  J Oncol       Date:  2022-09-15       Impact factor: 4.501

9.  Accuracy of Various Forms of Contrast-Enhanced MRI for Diagnosing Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Chun Zhao; Hongyan Dai; Juwei Shao; Qian He; Wei Su; Peng Wang; Qiuyue Tang; Junren Zeng; Song Xu; Juanjuan Zhao; Shutian Xiang
Journal:  Front Oncol       Date:  2021-12-07       Impact factor: 6.244

10.  Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression.

Authors:  Xinhua Zou; Wenzhe Fan; Miao Xue; Jiaping Li
Journal:  Cancer Manag Res       Date:  2021-05-18       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.